A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of mRNA-6231 in Healthy Adults

• Status: Recruiting
• Trial end date: 2022-11-15
• Target enrollment: 0
• Participant gender: All

Summary

The main goal of this study is to evaluate the safety and tolerability of escalating doses of a single subcutaneous (SC) administration of mRNA-6231.

• Phase: Phase 1
• Accepts Healthy Volunteers?: Accepts Healthy Volunteers

Details

• Lead Sponsor: ModernaTX, Inc.

Criteria

Key Inclusion Criteria:

• Understand and agree to comply with the study procedures and provide written informed consent

Key Exclusion Criteria:

• Has received any investigational product (for example, study drug, biologic, device) within 30 days or 5 elimination half-lives, whichever is longer

• Pregnant or lactating women

• Men and women of childbearing potential without effective contraception during the study

• Has any lab abnormalities or clinically significant medical condition that could interfere with the interpretation of study results or limit the participant's enrollment